The PCCP Gap: FDA Lets AI Models Change, Europe Asks Which Model You Meant

The PCCP Gap: FDA Lets AI Models Change, Europe Asks Which Model You Meant

FDA finalized its guidance on Predetermined Change Control Plans for AI-enabled devices in December 2024, resolving a design problem that has dogged adaptive medical AI since the first machine learning clearances. A PCCP lets a manufacturer define, in advance, the bounded ways a model is allowed to update after authorization, and FDA reviews that protocol once rather than re-reviewing every retrain meddeviceonline.com. For sponsors, this is the single most practical lifecycle tool FDA has produced for continuously learning systems. It converts an open-ended regulatory risk into a defined engineering task: specify the modification, the verification method, and the impact assessment, and the change proceeds without a new submission.

The decision problem is that Europe has no equivalent instrument, and its underlying legal test cuts the other way. A recent EU Court judgment clarified that medical device qualification turns on a product’s objective function and intended purpose, not merely its technical form goodlifesci.sidley.com. A model update that shifts decision logic, even within FDA’s pre-blessed PCCP boundaries, can plausibly change what the device does or how it does it. Under that test, the same update that requires zero new paperwork in the US can trigger a fresh conformity assessment in the EU. MDCG 2025-6 reinforces this by treating AI-specific bias mitigation and transparency obligations as live requirements through the AI Act’s dual compliance deadline of August 2026, not one-time checks at initial certification alphaindigo.nl.

This is not a paperwork asymmetry. It is a definitional one. FDA’s PCCP framework assumes the device’s identity is stable and only its performance envelope moves. The EU’s qualification test asks whether the device’s function has moved. A global change control plan built to satisfy FDA’s more permissive standard risks authorizing changes that Europe would classify as a new device requiring new CE marking, new notified body review, or reclassification entirely.

The integration path some vendors are pursuing, running ISO 13485 quality management and ISO 42001 AI governance through a single system so the same notified body can assess both MDR conformity and AI Act high-risk requirements under Article 43(3), addresses process efficiency but not this definitional gap dataart.com. A unified QMS makes audits cleaner. It does not tell you whether a specific model update crosses the EU’s functional threshold.

The practical implication for regulated developers building PCCPs today: draft the modification boundaries to the narrower standard first. If a proposed change would plausibly alter the device’s objective function or intended purpose under the EU test, treat it as out of scope for the PCCP globally, even where FDA would accept it under the US plan alone. Building the wider, FDA-permissive boundary and hoping it holds in Brussels is the error most likely to surface at the next EU market surveillance review, not the next FDA inspection.

The PCCP is a genuine regulatory advance. It just was not built with Europe’s device definition in mind, and retrofitting it after the fact is the harder version of this problem.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The core argument—that FDA’s PCCP framework and EU’s functional qualification test create a definitional asymmetry requiring developers to draft to the narrower standard—is logically coherent and well
Source & Claim Verification	Qwen · local	cleared. All factual claims are supported by citations, but some sources are not directly linked to specific claims, which could be improved for clarity.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects the regulatory distinctions between FDA’s PCCP and EU’s MDR/IVDR/AI Act requirements, but lacks explicit cross-references to specific clauses in ISO 42001 for AI gover
Technical Accuracy	Llama	cleared. The article accurately describes the differences between FDA’s Predetermined Change Control Plans and EU’s medical device qualification test, but could benefit from more technical depth on AI model up
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively presents a nuanced regulatory divergence without overstating the problem or promoting a single vendor’s solution, though some sources are tangential.
Novelty & Non-Duplication	Grok	held. The ‘PCCP Gap’ label and ‘draft to the narrower EU standard’ prescription are competent packaging, but the underlying FDA Dec 2024 guidance, EU qualification/function test, MDCG/AI Act dual-compliance
Validation	DeepSeek	cleared. The central claim that a model update allowed under an FDA PCCP could trigger a new conformity assessment in the EU is logically sound and supported by cited legal principles, but lacks a direct, real

Sources cited: 15. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.